Whether searching for clinically applicable biomarkers, designing a new companion diagnostic (CDx), or honing your study accrual and go-to-market strategies, we have the pharmaceutical development services to set you on the path to success.
The majority of cancer patients today are diagnosed and treated outside the context of clinical research—that is, in the real world.
To improve the efficiency, efficacy, and cost of clinical trials, pharmaceutical companies are using real-world data at each stage of the drug development process.
From biomarker discovery and validation to trial design and label expansion, QIAGEN Real-World Insights (RWI) provides pharmaceutical development services to help you bridge the gap between actionable insight and real-world action.
Oncology drug development can take up to 15 years, cost millions of dollars, and often relies on sparse data that doesn’t provide a full picture of a target patient population. But what if there’s a faster, safer, and more cost-effective way?
In the June 2020 issue of the Journal of Precision Medicine, Dr. Sheryl Elkin, CSO of QIAGEN Digital Insights, discusses the use of real-world genomic data to overcome the inefficiencies of drug development.
Dr. Anna Pokorska-Bocci of Debiopharm International shares her experience working with QIAGEN’s Real-World Insights team and how the customized analyses and offerings provided have enabled Debiopharm to accelerate drug development.
Drug development is a lengthy, complex, and costly process, entrenched with a high degree of uncertainty that a drug will actually succeed.
QIAGEN’s Real-World Insights (RWI) portfolio combines robust real-world genomic data from over 200,000 cancer cases and advanced analytics to shorten development timelines, optimize study designs, and improve patient outcomes.
QIAGEN Real-World Insights (RWI) is a professional and personalized pharmaceutical development service dedicated to finding the fastest, most cost-effective route to move therapies from research to market. RWI provides access to real-world genomic data, helping pharmaceutical companies confidently answer critical questions, such as:
Choose the best biomarkers and cancer indications for your molecularly targeted therapies
Identify appropriate patient cohorts and enhance your CDx design to improve stratification and success
Expand beyond the one biomarker, one drug paradigm with expert molecular profiling and drug-response analyses
More easily find the right patients and quickly move to recruitment and regulatory acceptance
Create and deliver bespoke RWI projects with a range of flexible options and services tailored to your unique requirements